Eisai Co. Ltd. and Biogen Inc. on Tuesday said their experimental Alzheimer’s drug significantly slowed cognitive and ...

Biogen plans to advance an experimental drug for Alzheimer's disease to late-stage testing despite disappointing mid-stage trial data, the company said Thursday. Biogen plans to move the drug into ...

Biogen is in focus because of a regulatory action date for a subcutaneous Alzheimer disease treatment. The update puts ...

Years after the launch of a controversial Alzheimer’s drug nearly crippled the company, Biogen is moving an experimental treatment into late-stage trials. Wall Street is not yet sold. The biotech on ...

Add Yahoo as a preferred source to see more of our stories on Google. Biogen will progress diranersen to a Phase III trial in Alzheimer's disease. Credit: Jeviredurose_design / Shutterstock.com.

BOSTON--An injected version of Eisai and Biogen's Alzheimer's drug Leqembi works as well as the current intravenous ...

CHICAGO, July 14 (Reuters) - The lowest dose of Biogen's anti-tau Alzheimer's drug diranersen, which missed its primary goal in a midstage trial, reduced cognitive decline in five of six Alzheimer's ...

If Novo Nordisk A/S’s wildly popular weight-loss drug succeeds in a highly anticipated trial for Alzheimer’s disease, Biogen Inc.’s Chief Executive Officer Chris Viehbacher doesn’t see it as a ...

Biogen shares fell Friday after the head of the FDA called for an investigation into the recent approval of the company's Alzheimer's drug, Aduhelm. Acting FDA Commissioner Dr. Janet Woodcock asked ...

Diranersen presentation will feature Phase 2 CELIA data in early Alzheimer’s disease, including clinical, biomarker and safety results for Biogen’s investigational tau-targeting ASO, following topline ...

In August, the U.S. Food and Drug Administration (FDA) stated that it is requiring an additional MRI scan for Alzheimer's patients receiving Leqembi (lecanemab), citing safety concerns over a rare but ...